Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ENTA with free AI briefings, catalyst countdowns, and dilution alerts.

ENTA · Enanta Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$211.5M Cash on Hand
74.1mo Cash Runway
Follow ENTA by email Get an email when ENTA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ENTA, unsubscribe in one click. Privacy

📣 What ENTA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zelicapavir RSV Phase 2/3 · NCT07908381 Recruiting
EDP-938 RSV Infection Phase 2 · NCT05568706 Completed
EDP-323 Dose Regimen 1 RSV Infection Phase 2 · NCT06170242 Completed
EDP-323 Dose Regimen 2 RSV Infection Phase 2 · NCT06170242 Completed
EDP-420 / Duration of Treatment - 3 days Community Acquired Pneumonia Phase 2 · NCT00270517 Unknown
EDP-305 Dose 2 Non-Alcoholic Steatohepatitis Phase 2 · NCT03421431 Completed
EDP-305 Dose 1 Non-Alcoholic Steatohepatitis Phase 2 · NCT03421431 Completed
EDP-305 Primary Biliary Cholangitis Phase 2 · NCT03394924 Completed
EDP-938 Dose 1 RSV Infection Phase 2 · NCT03691623 Completed
EDP-235 COVID-19 Phase 2 · NCT05616728 Completed
EDP-938 Dose 2 RSV Infection Phase 2 · NCT03691623 Completed
EDP-938 Dose 3 RSV Infection Phase 2 · NCT03691623 Completed
Telithromycin Community Acquired Pneumonia Phase 2 · NCT00270517 Unknown
EDP-938 Dose 4 RSV Infection Phase 2 · NCT03691623 Completed
intraconazole NASH - Nonalcoholic Steatohepatitis Phase 1 · NCT03213145 Completed
EDP239 Hepatitis C Phase 1 · NCT01856426 Completed

Also used in these trials (approved or third-party drugs, not ENTA's own candidates): Itraconazole, Prednisone, Fluconazole, Midazolam Hydrochloride, Rifampin, Tacrolimus Extended-Release, Caffeine, Dabigatran Etexilate, Cyclosporine, Carbamazepine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ENTA holds $211.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 74.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENTA files for a raise →

👥 Who Owns ENTA

Insiders 4.7% Other 5%+ holders 15.5% Institutions (182 holders) 79.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Dapice Joshua J. 5%+ holder (13G) 2,816,862 9.67% 2025-12-31
ADAR1 Capital Management, LLC Institution (13G, 5%+) 1,733,320 5.95% 2026-09-30
Jay R. Luly, Ph.D. 5%+ holder (13D) 1,703,616 5.85% 2025-02-12
BlackRock Portfolio Management LLC Institution (13G, 5%+) 1,560,091 5.36% 2026-09-30
Jay R. Luly
President and CEO, Director · +310,000 options
Insider 871,871 2.99% 2026-02-12
Yat Sun Or
Chief Scientific Officer · +110,000 options
Insider 374,854 1.29% 2026-02-12
Brendan Luu
Chief Business Officer · +90,000 options
Insider 41,634 0.14% 2026-02-12
Tara Lynn Kieffer
Chief Product Strategy Officer · +100,000 options
Insider 33,925 0.12% 2026-02-12
Scott T. Rottinghaus
Chief Medical Officer · +110,000 options
Insider 23,787 0.08% 2026-08-08
Harry R. III Trout
Vice President, Finance (Principal Finan · +12,925 options
Insider 16,348 0.06% 2025-12-05
Kathleen S. Capps
Executive Director of Accounting, Contro · +6,325 options
Insider 8,377 0.03% 2025-12-05
Matthew Paul Kowalsky
Chief Legal Officer · +90,000 options
Insider 3,591 0.01% 2026-02-12

Share count 29,125,402 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ENTA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENTA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.